Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
|
|
- Gavin Ward
- 6 years ago
- Views:
Transcription
1 The Journal of International Medical Research 2011; 39: Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department of Epidemiology, Wuxi Infectious Disease Hospital, Wuxi, China This retrospective study examined 220 Chinese chronic hepatitis B virus carriers over 5 years. After initial liver biopsy, liver function tests and serological analysis, patients underwent further tests of liver function and hepatitis B seromarkers at 6- month intervals. Second and third liver biopsies were performed in 56 and 23 patients, respectively. Liver pathology was classified according to inflammatory activity (G 0 G 4 ) and degree of fibrosis (S 0 S 4 ). A significantly greater proportion of hepatitis B e antigen antibody-positive patients had a more severe level of inflammation and fibrosis than patients who were hepatitis B e antigen (HBeAg)- positive. Abnormal inflammation ( G 2 ) occurred in 122 (55.5%) patients. Hepatitis B reactivation occurred in 35 (15.9%) patients: 33 had obvious liver inflammation at the initial biopsy ( G 2 ) and only two had a low level of liver inflammation (G 0 ). The hepatitis B reactivation rate was significantly related to age but not to gender. Hepatitis B surface antigen clearance was 1.55% per year and HBeAg seroconversion was 5.36% per year. In conclusion, hepatitis B reactivation was closely correlated with age and the level of liver inflammation. KEY WORDS: CHRONIC HEPATITIS B VIRUS CARRIER; HEPATITIS B REACTIVATION; LIVER BIOPSY; LIVER PATHOLOGY Introduction Chronic hepatitis B infection is a global public health problem that is estimated to cause between and 1.2 million deaths annually. 1 3 In China, about 10% of the population is positive for hepatitis B surface antigen (HBsAg); this proportion has declined over time. Alanine amino - transferase (ALT) levels are often normal for a long time in patients who are HBsAgpositive; 3 some HBsAg-positive patients have occult hepatitis B virus (HBV) infection. 3 In 2007, reactivation of hepatitis B was defined in the American Association for the Study of Liver Diseases Practice Guidelines 4 as the reappearance of active necroinflammatory disease in the liver of a person who is known to be an inactive HBsAg carrier or who has resolved hepatitis B. Such patients have clinical symptoms and signs, such as weakness, anorexia, abnormal liver function tests and hepatosplenomegaly. Some will eventually develop hepatic failure, hepatocirrhosis and primary hepatocellular carcinoma. 5 This retrospective study examined the records of 220 chronic HBV carriers in Wuxi, China, over a 5-year period, observing their clinical symptoms, liver biopsy, liver function and viral seromarker results. 71
2 Patients and methods PATIENTS Chronic HBV carriers presenting as outpatients at Wuxi Infectious Disease Hospital, Wuxi, China, from January 2001 to December 2003 were identified and their records over the subsequent 5-year period were examined. All patients underwent family history and clinical symptom inquiry, laboratory assessment (serum analysis for liver function, HBV seromarkers and HBV DNA), and histopathological assessment (liver biopsy) at their initial outpatient visit. The diagnosis of chronic HBV carrier was based on the criteria set out by the Chinese Medical Association. 6 Patients with other hepadnavirus infections, toxic or druginduced liver disease, alcoholic liver disease or fatty liver were excluded from the study. The study protocol was approved by the Ethics Committee of Wuxi Infectious Disease Hospital. Patients provided verbal permission for their data and records to be used in this study. HISTOPATHOLOGICAL ASSESSMENT Liver biopsy involved the 1-second procedure using a Tru-cut needle (HS Hospital Service, Aprilia, Italy), removing at least 1.5 cm of liver tissue. The samples were fixed in 4% neutral formaldehyde, embedded in paraffin and cut into 5 µm thick sections. Haematoxylin and eosin staining, reticular fibre staining and Masson staining were then performed sequentially. Histopathological assessment was made according to the criteria established by the Chinese Medical Association in 2000: 6 level of inflammatory activity was classified as G 0 G 4 and the degree of fibrosis was classified as S 0 S 4. 7,8 All slides were examined independently by two pathologists. LABORATORY ASSESSMENT Blood samples were taken from all patients for laboratory analysis. Liver function test (measurement of ALT) was performed using a fully automated biochemical analyser (Abbott Laboratories, Chicago, IL, USA). HBV seromarkers, including HBsAg, antibody to HBsAg (anti-hbs), hepatitis B e antigen (HBeAg), antibody to HBeAg (anti-hbe) and antibody to hepatitis B core antigen (anti- HBc), were detected by enzyme-linked immunosorbent assay (ELISA) using a fully automated ELISA analyser (Abbott Laboratories). The level of HBV DNA was detected using quantitative fluorescent polymerase chain reaction (PCR) (LightCycler PCR system; Roche, Indianapolis, IN, USA); a negative result for HBV DNA was defined as < copies/ml. FOLLOW UP Patients were followed up at 6-month intervals for 5 years. Each visit included symptom inquiry and serum analysis for liver function and HBV seromarkers. Some patients underwent a second or third liver biopsy to monitor changes in liver inflammation and fibrosis. Patients with inflammatory activity G 2 were advised to rest and were given vitamin and silymarin preparations. 9 Patients with high viral titres of HBV DNA (> 10 5 copies/ml) were given antiviral agents, mainly nucleoside analogues. 10,11 All other patients maintained their normal daily activities and were not given any drug treatment. STATISTICAL ANALYSIS Between-group differences were analysed using the rank sum test or the χ 2 test. A P- value < 0.05 was considered to be statistically significant. Results PATIENTS A total of 220 chronic HBV carriers were 72
3 included in the study. Of these, 156 (70.9%) were male and 64 (29.1%) were female. The patients ages at the first visit ranged from 12 to 62 years and their HBsAg-positive history ranged from 1 to 25 years in duration. None of the patients had received any drug treatments and 147 (66.8%) had a family history of hepatitis B. LIVER FUNCTION AND HBV SEROMARKERS A total of 168 patients (76.4%) were positive for HBeAg and all these had normal ALT levels throughout the follow-up period. The remaining 52 patients (23.6%) were positive for anti-hbe. There were also 135 patients (61.4%) who were positive for anti-hbc. HBV DNA was detected in 93 patients (42.3%) and, of these 51 (54.8%) had HBV DNA levels > copies/ml and were considered to be HBV DNA-positive. Viral titres > 10 5 copies/ml were found in 14 patients and they were given antiviral agents, mainly nucleoside analogues. 10,11 LIVER PATHOLOGY The level of inflammatory activity and the degree of liver fibrosis in the initial liver biopsies in the 220 chronic HBV carriers are given in Tables 1 and 2, respectively, divided according to their HBeAg status. Inflammatory activity was abnormal ( G 2 ) in 55.5% of patients. A significantly greater proportion of anti-hbe-positive patients had a more severe level of inflammation and fibrosis than the HBeAg-positive patients (χ 2 = , P = for inflammation; χ 2 = , P = for fibrosis). TABLE 1: Level of liver inflammatory activity according to hepatitis B e antigen status in chronic hepatitis B virus carriers Level of inflammation Status n G 0 G 1 G 2 G 3 G 4 HBeAg-positive (11.9) 61 (36.3) 57 (33.9) 20 (11.9) 10 (6.0) Anti-HBe-positive 52 4 (7.7) 13 (25.0) 12 (23.1) 17 (32.7) 6 (11.5) Total (10.9) 74 (33.6) 69 (31.4) 37 (16.8) 16 (7.3) Data presented as number, n (%) of patients. Between-group statistical significance by rank sum test (χ 2 = , P = ). HBeAg, hepatitis B e antigen; anti-hbe, antibody to hepatitis B e antigen. TABLE 2: Degree of liver fibrosis according to hepatitis B e antigen status in chronic hepatitis B virus carriers Degree of fibrosis Status n S 0 S 1 S 2 S 3 S 4 HBeAg-positive (10.1) 57 (33.9) 54 (32.1) 25 (14.9) 15 (9.0) Anti-HBe-positive 52 5 (9.6) 10 (19.2) 13 (25.0) 14 (26.9) 10 (19.3) Total (10.0) 67 (30.5) 67 (30.5) 39 (17.7) 25 (11.3) Data presented as number, n (%) of patients. Between-group statistical significance by rank sum test (χ 2 = , P = ). HBeAg, hepatitis B e antigen; anti-hbe, antibody to hepatitis B e antigen. 73
4 When patients were divided according to age ( 40 years and < 40 years), there was no significant difference between the two groups in the proportions of patients with a G 0 versus a G 2 level of liver inflammation. The degree of liver fibrosis, however, was significantly different (χ 2 = 7.37, P < 0.01); a significantly greater proportion of patients aged 40 years had more severe liver fibrosis than those aged < 40 years (Table 3). HEPATITIS B REACTIVATION During the 5-year follow-up period, 35 of the 220 patients (15.9%) showed symptoms of hepatitis B reactivation, including clinical weakness, anorexia, abnormal liver function tests and hepatosplenomegaly. Four were amongst the 69 patients with an initial G 2 level of inflammation (5.8% of those with an initial G 2 level), 21 were amongst the 37 patients with an initial G 3 level of inflammation (56.8% of those with an initial G 3 level) and eight were amongst the 16 patients with an initial G 4 level of inflammation (50.0% of those with an initial G 4 level). Only two were amongst the 98 patients originally classified as G 0 (2.0% of those with an initial G 0 level). Analysis using the χ 2 test revealed that the incidence of hepatitis B reactivation was statistically related to the level of liver inflammation (G 0 1 versus G 2, χ 2 = 25.41, P < 0.01). Among the 35 patients who showed hepatitis B reactivation, 27 (77.1%) were aged 40 years. A χ 2 test analysis demonstrated that the relationship between age and hepatitis B reactivation was statistically significant (χ 2 = 6.72, P < 0.01). Twenty-two of the 35 patients (62.9%) with hepatitis B reactivation were male; amongst the 220 patients studied, hepatitis B reactivation was seen in 22 out of 156 (14.1%) of the male patients and in 13 out of 64 (20.3%) of the female patients. There was no statistically significant relationship between hepatitis B reactivation in chronic HBV carriers and gender. CHANGES IN LIVER PATHOLOGY Further liver biopsies were performed in a number of patients 2 4 years after the first biopsy. Fifty-six patients underwent a second liver biopsy. Of these, 30 patients had G 0 liver inflammation in the first liver biopsy and 26 still showed G 0 inflammation at the second biopsy, three patients had progressed to G 2, and one patient showed G 3 levels of inflammation. Among the 14 patients with G 2 liver inflammation in the first liver biopsy, seven patients still showed G 2 inflammation, five patients had progressed to G 3 and two patients had progressed to G 4. Among the seven patients TABLE 3: Level of liver inflammatory activity and degree of liver fibrosis according to age in chronic hepatitis B virus carriers Level of inflammation Degree of fibrosis Age n G 0 G 2 S 0 S 1 S 2 < 40 years (46.8) 67 (53.2) 56 (44.4) 70 (55.6) 40 years (41.5) 55 (58.5) 25 (26.6) 69 (73.4) Total (44.5) 122 (55.5) 81 (36.8) 139 (63.2) Data presented as number, n (%) of patients. Between-group statistical significance by χ 2 test (χ 2 = 7.37, P < 0.01) for degree of fibrosis; no betweengroup statistical significance by χ 2 test for level of inflammation. 74
5 with G 3 liver inflammation in the first liver biopsy, six patients still showed G 3 inflammation and one patient had improved to G 2. Among the five patients with G 4 in the first liver biopsy, two patients still showed G 4 inflammation and two had improved to G 3. Twenty-three patients underwent a third liver biopsy. Of these, 10 patients had G 2 levels of inflammation in the second liver biopsy and eight still showed G 2 inflammation in the third biopsy whereas two had improved to G 1. Among the 11 patients with G 3 levels of inflammation in the second liver biopsy, two still showed G 3 levels in the third biopsy, whereas the remaining nine had improved to G 2 or G 1 inflammation levels. Among the two patients with G 4 levels of inflammation in the second liver biopsy, one patient had improved to G 3 and another to G 2 in the third liver biopsy. CHANGES IN HBV SEROMARKERS Clearance of HBsAg occurred in only 17 of the 220 chronic HBV carriers studied over the course of 5 years, giving an HBsAg clearance rate of 1.55% per year. HBeAg seroconversion occurred in 45 of the 168 patients who were HBeAg-positive at the start of the study, giving an HBeAg clearance rate of 5.36% per year. Among these 45 patients, HBeAg seroconversion occurred spontaneously in 36 patients and after nucleoside analogue treatment, given on the basis of high viral titres of HBV DNA, in the other nine patients. Discussion With raised health awareness in recent years, chronic HBV carriers are increasingly wanting treatments that are less toxic. There is also still an active debate regarding whether chronic HBV carriers need treatment at all and, if so, how. 12 Liver inflammation and fibrosis in chronic HBV carriers can be easily diagnosed using the 1-second liver biopsy, 13,14 which can help doctors to make a correct assessment of disease state and, therefore, the treatment needs of the patient. 4,15 17 In addition, the 1-second liver biopsy is easy to perform, causes little damage and has few complications, improving the likelihood that patients will be willing to undergo the procedure. There are few reports on the long-term follow up of chronic HBV carriers worldwide. Brechot et al. 18 studied the relationship between heavy use of alcohol and hepatitis B reactivation in chronic HBV carriers. They concluded that alcohol was associated with liver cell denaturalization and immune function depression, which provided an opportunity for HBV to survive and replicate. They emphasized that alcoholic liver damage was just one factor in the reactivation of hepatitis B. Some patients eventually developed hepatocirrhosis or hepatic carcinoma. Chen s research group 19,20 demonstrated that long-term high titres of serum HBV DNA but not ALT were an independent risk factor for progression from chronic hepatitis B to primary hepatic carcinoma. Gigi et al. 21 performed a liver biopsy in 35 chronic HBV carriers. In 32 patients the histological activity index was > 4; of these, 22 patients were given antiviral agents and their health improved. Among the 220 chronic HBV carriers in the present 5-year study, 35 patients (15.9%) developed clinical symptoms and changes in liver function related to hepatitis B reactivation. There was a close correlation between hepatitis B reactivation and liver inflammation, with reactivation eventually occurring in over half of the patients with severe liver inflammation ( G 3 ). Analysis of the data showed that age but not gender 75
6 were significantly related to hepatitis B reactivation in chronic HBV carriers. In the present study, only 10.9% of patients had inflammatory activity classified as G 0 and 10.0% had liver fibrosis classified as S 0. Although most of the chronic HBV carriers had mild or severe liver inflammation and fibrosis, 11.3% of the patients had histological cirrhosis (S 4 ) despite having no clinical symptoms, normal serology and normal appearance of the liver. More anti-hbe-positive patients than HBeAg-positive patients had higher levels of inflammation and fibrosis, indicating that the pathological changes were not markedly alleviated by seroconversion. This may be due to the induction of immune resistance by HBeAg, allowing HBV to escape immune clearance. It may be that, in anti-hbepositive patients, clearance of serum HBeAg leads to an increase in cytotoxic T-cells, which invade the liver and attack infected liver cells, aggravating liver damage, which is in agreement with other research performed in China. 22,23 When analysed according to age, there was no significant difference between patients of age 40 years and those < 40 years in the proportions of patients with a G 0 versus a G 2 level of liver inflammation, whereas a significantly greater proportion of the older group had a higher degree of liver fibrosis compared with the younger group. This may be due to occult deterioration. At the immune clearance stage and the inactive or low replication stages, liver inflammation is repaired, whereas fibrotic tissue remains, and this is consistent with the observations of Fan et al. 24 The results of subsequent liver biopsies during follow up indicated that patients with normal liver tissue in the initial liver biopsy were usually stable and their liver tissue could remain normal for several years. Once liver damage appeared, as evidenced by G 3 or G 4 levels of inflammation, liver function became abnormal; this condition could last for a long time and rarely showed recovery, although a few patients with liver inflammation at the G 3 or G 4 level appeared to show a degree of histological recovery. The G 2 level of liver inflammation was an unstable status, with five out of 14 patients progressing to G 3 and two progressing to G 4 by the time of the second liver biopsy. It is clear, therefore, that patients with G 2 liver inflammation need to be closely followed, in particular with liver biopsies, to detect the development of cirrhosis. 12,25 During follow-up, a few patients showed spontaneous clearance of HBsAg together with HBeAg seroconversion. This could be due to the effect of enhanced immune function over the course of the disease. These patients mostly only had minor abnormalities in the initial liver biopsy and the second liver biopsy usually indicated alleviation of liver inflammation though not to an absolutely normal level. In conclusion, hepatitis B reactivation in chronic HBV carriers was closely correlated with age and the level of liver inflammation. Conflicts of interests The authors had no conflicts of interest to declare in relation to this article. Received for publication 26 July 2010 Accepted subject to revision 31 August 2010 Revised accepted 21 October 2010 Copyright 2011 Field House Publishing LLP References 1 Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J 76
7 Viral Hepat 2004; 11: Lee WM: Hepatitis B virus infection. N Engl J Med 1997; 337: World Health Organization: Hepatitis B. Fact Sheet 204. Geneva: World Health Organization, revised 2008 (available at: mediacentre/factsheets/fs204/en/index.html). 4 Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007; 45: Merican I, Guan R, Amarapuka D, et al: Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: Chinese Society of Infectious Diseases and Parasitology of the Chinese Medical Association, Chinese Society of Hepatology of the Chinese Medical Association: The programme of prevention and cure for viral hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000; 8: [in Chinese]. 7 Desmet VJ, Gerber M, Hoofnagle JH, et al: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: Scheuer PJ, Lefkowitch JH: Liver Biopsy Interpretation, 7th edn. London: Elsevier, 2006; pp Han YN: Identification of acute self-limited hepatitis B among patients presenting with hepatitis B virus-related acute hepatitis: a hospital-based epidemiological and clinical study. J Int Med Res 2009; 37: Tang LL, Sheng JF, Xu CH, et al: Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res 2009; 37: Lin M, Yang LY, Li WY, et al: Inhibition of the replication of hepatitis B virus in vitro by oxymatrine. J Int Med Res 2009; 37: Lai M, Hyatt B, Afdahl N: Role of liver biopsy in patients with normal ALT and high HBV DNA. Hepatology 2005; 42(suppl): 720A [abstract]. 13 Luo KX (ed): Hepatitis B: Basic Biology and Clinical Science, 2nd edn. Beijing: People s Medical Publishing House, 2001; p Zhang TH, Qian YC, Li XS: A histologic study of asymptomatic HBsAg carriers. Zhonghua Nei Ke Za Zhi 1985; 24: , 445 [in Chinese]. 15 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association: The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2005; 13: [in Chinese]. 16 Keeffe EB, Dieterich DT, Han SH, et al: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: Lok AS: HBV treatment strategies should be based on published data. AGA Perspectives 2006; 2: Brechot C, Nalpas B, Feitelson MA: Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med 1996; 16: Iloeje UH, Yang HI, Su J, et al: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: Chen CJ, Yang HI, Su J, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: Gigi E, Lalla T, Orphanou E, et al: Long term follow-up of a large cohort of inactive HBsAg(+)/HBeAg( )/anti-hbe(+) carriers in Greece. J Gastrointestin Liver Dis 2007; 16: Xu Q, Shu X, Chen L, et al: Pathological changes between HBeAg and anti-hbe in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2001; 9: [in Chinese, English abstract]. 23 Yuan PG: Direct more attention to chronic hepatitis B patients with normal serum alanine aminotransferase levels. Zhonghua Gan Zang Bing Za Zhi 2008; 16: [in Chinese]. 24 Fan HM, Yang Z, Zhang CL, et al: Liver histopathological features of chronic HBV carriers and inactive HBsAg carriers. Zhonghua Gan Zang Bing Za Zhi 2007; 15: [in Chinese, English abstract]. 25 Saadeh S, Cammell G, Carey WD, et al: The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: Author s address for correspondence Dr ZH Lu Department of Epidemiology, Wuxi Infectious Disease Hospital, 88 Xingyuan Zhong Road, Wuxi , China. Lu_z_h@126.com 77
HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationY. Xiang*, P. Chen*, J.R Xia and L.P. Zhang
A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies Y. Xiang*, P. Chen*,
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationAlam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1
Bangladesh Med Res Counc Bull 2014; 40: 92-56 Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationPharmacologyonline 2: 3-7 (2011) Case Report Singhal et al.
A CASE REPORT OF CLI ICAL ADVERSE EVE TS OF TELBIVUDI E I HEPATITIS B PATIE TS Manmohan Singhal 1, Dhaval Patel 1, Pankaj shah 2 1 School of Pharmaceutical Sciences, Jaipur National University, Jaipur,
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationC hronic hepatitis B (CHB) virus infection affects more
161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationDNA 2 91% (185/203), 82% (75/91), 75% (47/63), 62% (26/42) 200,000, 20, ,999, 2,000-19,999, <2,000 ( P
Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen Negative Chronic Hepatitis B Virus Infection? George V. Papatheodoridis, 1 Emanuel K. Manesis,
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More informationA preliminary report on the influence of baseline cellular immunity to the therapeutic responses of peg-interferon
146 2009 9 4 3 Journal of Microbes and Infection, September 2009, Vol. 4, No. 3 e 2a 1, 2, 1, 1, 1, 1, 1, 1 1., 200025; 2., 200032 : ( CHB) ( IFN), IFN IFN, e ( HBeAg) CHB 19, 14, IFN- 2a 180 g, 1, 48,
More informationHepatitis B (HBV) infection is a major worldwide
Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in a Cohort Chronically Infected with Hepatitis B Virus Josephine Simonetti, 1 Lisa Bulkow, 2 Brian J. McMahon, 1,2 Chriss
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationBSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D
BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D Amar Paul Dhillon Royal Free & University College Medical School Thurs 10
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationChallenges in therapy of chronic hepatitis B
Journal of Hepatology 39 (2003) S230 S235 www.elsevier.com/locate/jhep Challenges in therapy of chronic hepatitis B Jay H. Hoofnagle* Division of Digestive Diseases and Nutrition, National Institute of
More informationChronic infection with hepatitis B virus (HBV) is still a
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI
More informationDiagnosis and Management of Chronic Hepatitis B virus Infection
1/2009 iagnosis and Management of Chronic Hepatitis B virus Infection lab.update 1. Introduction 2. Course of the chronic infection 3. Importance of the virus load 4. Monitoring of the chronic infection
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationInternist Diagnosis and Management of Chronic Hepatitis B Virus Infection
UPDATE IN OFFICE MANAGEMENT Internist Diagnosis and Management of Chronic Hepatitis B Virus Infection Brian J. McMahon, MD, a Joan Block, RN, BSN, b Barbara Haber, MD, c Thomas London, MD, d James A. McHugh,
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationXiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;
Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome
More informationSojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh
Original article Annals of Gastroenterology (2013) 26, 1-5 Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationDynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B
Vol.2, No.7, 736-741 (2010) doi:10.4236/health.2010.27112 Health Dynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B Bo Liu, Jun Li*, Yaping Han,
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationIntron A HEPATITIS B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.01 Subject: Intron A Hepatitis B Page: 1 of 8 Last Review Date: September 18, 2015 Intron A HEPATITIS
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationLab Underwriting Puzzler. Presented by: Bill Rooney, M.D.
Lab Underwriting Puzzler Presented by: Bill Rooney, M.D. Obtaining Best Results from this presentation For best results please do the following: Select Slide Show from the menu option on top Select From
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationChronic hepatitis B (CHB) infection is a large
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More information[DOI] /j.issn , China
Med J Chin PLA, Vol. 41, No. 5, May 1, 2016 351 HBsAg HBs S N- [ ] (HBV)HBsAg+ HBs S (MHR) N- HBsAg+ HBs 284 HBsAg+ HBs 314 HBsAg HBV S 1 MHR N- N- S/S HepG2 HBsAg+ HBs MHR N- 11.3%(32/284) HBsAg 2.9%(9/314)(P
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationFaculty: Hannah M. Lee, MD Geneve Allison, MD
pmicme Updates April 11, 2012 Anaheim, California Faculty: Hannah M. Lee, MD Geneve Allison, MD Session 3: SCALE HBV: Screening, Counseling and Linkage to Care Education Learning Objectives 1. Apply the
More informationRelation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationResearch Article HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review
Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 672614, 6 pages http://dx.doi.org/10.1155/2013/672614 Research Article HBV Genotype B/C and Response to Lamivudine Therapy:
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationEffect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular invasion of hepatocellular carcinoma
Qu et al. Infectious Agents and Cancer (2019) 14:2 https://doi.org/10.1186/s13027-019-0219-8 RESEARCH ARTICLE Open Access Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular
More informationOriginal article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B
Antiviral Therapy 2011; 16:469 477 (doi: 10.3851/IMP1772) Original article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B Young Eun Chon 1, Seung Up Kim
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More information